Dave Domzalski, CEO, Foamix Pharmaceuticals reminds us that acne is the most common skin condition affecting 50 million people in the US alone, how little has changed in the treatment of outbreaks, and how side effects of commonly prescribed acne treatments often result in many people discontinuing use leaving their acne unresolved.  Foamix is in late stage development of a topical form of minocycline, usually prescribed as an oral antibiotic, that is applied directly to the skin as a foam and that is showing fewer side-effects and greater impact. #acne #acneprone #AcneAwareness #skincare #clearskin #dermatology #dermatologist  Foamix Pharmaceuticals